Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

February 28, 2027

Conditions

BRCA1 MutationBRCA2 MutationBRCA MutationPALB2 Gene MutationCheckpoint Kinase 2 Gene MutationATM Gene Mutation

Interventions

DRUG

Olaparib

Given orally

DRUG

ASTX727

Given Orally

Trial Locations (1)

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Pamela Munster

OTHER